22:48 , Mar 9, 2017 |  BC Innovations  |  Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
21:33 , Feb 24, 2017 |  BC Week In Review  |  Company News

Ablexis, J&J deal

Ablexis granted Johnson & Johnson’s Janssen Biotech Inc. unit perpetual, non-exclusive rights to use Ablexis' AlivaMab Mouse transgenic mouse platform for antibody drug discovery and development. Ablexis will receive an eight-figure upfront payment. The companies...
21:56 , Jan 20, 2017 |  BC Week In Review  |  Company News

Ablexis, Tri-Institutional Therapeutics Discovery Institute deal

Ablexis granted the institute non-exclusive rights to use the AlivaMab Mouse transgenic mouse technology to discover human antibodies. Ablexis will receive an eight-figure payment. Ablexis declined to disclose financial terms, and Tri-TDI did not respond...
07:00 , Aug 5, 2013 |  BioCentury  |  Finance

mAbs for the masses

mAbs for the masses Even though Harbour Antibodies B.V. is one of at least three biotechs seeking to broadly out-license their transgenic mouse platforms, Atlas Venture was attracted to the deal because the small investment...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Company News

Ablexis deal

Ablexis granted an undisclosed pharmaceutical company non-exclusive rights to AlivaMab Mouse transgenic mouse technology to discover human antibodies. The pharma will make a "seven-figure pre-delivery" and an "eight-figure post-delivery" payment to Ablexis. Details were not...
08:00 , Feb 27, 2012 |  BioCentury  |  Emerging Company Profile

Kymab: More mAb diversity

Kymab Ltd. is developing its Kymouse transgenic mouse platform to generate a greater repertoire of human mAbs than it says can be done with competing technologies. With the Wellcome Trust backing the newco, management plans...
07:00 , Sep 5, 2011 |  BioCentury  |  Strategy

Back to School: Innovation & collaboration

Since the economic downturn of 2008, doom has become ingrained in the biopharma narrative. According to the mantra, budgets for great science have flatlined. New startups can't find VC money to translate great science because...
08:00 , Jan 31, 2011 |  BioCentury  |  Strategy

Selling mouse futures

The two most popular mouse platforms to discover human antibodies, Abgenix Inc. 's XenoMouse and Medarex Inc. 's HuMAb Mouse, have been licensed only once since Abgenix was acquired by Amgen Inc. in 2005 and...
07:00 , Nov 1, 2010 |  BC Week In Review  |  Company News

Ablexis, Pfizer deal

Ablexis granted Pfizer and four undisclosed pharma companies non-exclusive rights to use its AlivaMab Mouse transgenic mouse technology to discover human antibodies. Ablexis will receive a seven-figure upfront payment from each pharma and is eligible...
00:02 , Oct 27, 2010 |  BC Extra  |  Company News

Ablexis unveils AlivaMab Mouse deals

Ablexis LLC (San Francisco, Calif.) granted Pfizer Inc. (NYSE:PFE) and four other pharma companies non-exclusive rights to use its AlivaMab Mouse transgenic mouse technology to discovery human antibodies. Ablexis will receive a seven-figure upfront payment...